Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Lippman

Showing results (221-230 of 240) with videos related to

Pageof 24
Sort By:
Cancer Causes & Control : CCC|September 13, 2001
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)A Hoque, D Albanes, S M Lippman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 23, 1997
Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancerM R Spitz, R S McPherson, H Jiang, et al.
Journal of the National Cancer Institute|October 28, 1998
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapyL Mao, A K El-Naggar, V Papadimitrakopoulou, et al.
Journal of the National Cancer Institute|January 6, 2000
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expressionD M Shin, L Mao, V M Papadimitrakopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinomaD M Shin, B S Glisson, F R Khuri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2000
Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancerF R Khuri, R Lotan, B L Kemp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinomaG L Clayman, A K el-Naggar, S M Lippman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 8, 2001
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trialF R Khuri, E S Kim, J J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trialD M Shin, F R Khuri, B Murphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancerM Duvic, B Helekar, C Schulz, et al.
Pageof 24

Showing results (221-230 of 240) with videos related to

Sort By:
Pageof 24
Cancer Causes & Control : CCC|September 13, 2001
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)A Hoque, D Albanes, S M Lippman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 23, 1997
Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancerM R Spitz, R S McPherson, H Jiang, et al.
Journal of the National Cancer Institute|October 28, 1998
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapyL Mao, A K El-Naggar, V Papadimitrakopoulou, et al.
Journal of the National Cancer Institute|January 6, 2000
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expressionD M Shin, L Mao, V M Papadimitrakopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinomaD M Shin, B S Glisson, F R Khuri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2000
Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancerF R Khuri, R Lotan, B L Kemp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinomaG L Clayman, A K el-Naggar, S M Lippman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 8, 2001
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trialF R Khuri, E S Kim, J J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trialD M Shin, F R Khuri, B Murphy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancerM Duvic, B Helekar, C Schulz, et al.
Pageof 24